[The effect of fructose-1,6-diphosphate and phosphoenolpyruvate on the course of early occlusion and reperfusion arrhythmias in rats].
Fructose-1,6-diphosphate (150 and 50 mg/kg) and phosphoenolpyruvate (0.5 and 0.1 mg/kg) decreased the development of ventricular tachycardia, ventricular fibrillation and the intensity of ventricular extrasystoles after coronary occlusion in experimental rats. Both compounds were active as anti-fibrillation agents on reperfusion arrhythmias. Fructose-1,6-diphosphate potentiated the effect of lidocaine.
V P
VP
Balashov
Ia V
IaV
Kostin
D G
DG
Sedova
L N
LN
Sernov
V V
VV
Gatsura
D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy* / Q000209:etiology; D003327:Coronary Disease / Q000150:complications* / Q000188:drug therapy; D004353:Drug Evaluation, Preclinical; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D005635:Fructosediphosphates / Q000627:therapeutic use*; D008012:Lidocaine / Q000627:therapeutic use; D015428:Myocardial Reperfusion Injury / Q000150:complications* / Q000188:drug therapy; D010728:Phosphoenolpyruvate / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar
D000889:Anti-Arrhythmia Agents; D005635:Fructosediphosphates; D010728:Phosphoenolpyruvate; D008012:Lidocaine; C029063:fructose-1,6-diphosphate